Citations

Clear

65 citation(s) found for "Karon, M".

Abstract 18738: Pulmonary Artery Systolic Pressures Increase With Aging: A Longitudinal, Population Based Study
Chandra, Suparna, Redfield, Margaret M. , Karon, Barry L., Rodeheffer, Richard J. , Kane, Garvan C.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a18738 Get It

Background: A community based, cross-sectional echo survey demonstrated that pulmonary artery systolic pressure (PASP) increases with age and that PASP is associated with systemic arterial stiffness, Doppler estimated left ventricular (LV) filling pressures and lung function. Longitudinal assessment of PASP is needed to confirm cross-sectional observations. Objectives: To assess the whether PASP changes over time in longitudinally studied subjects and determine whether changes in PASP are associated with changes in systemic vascular stiffness, LV filling pressures or lung function. Methods: A random sample (n=2042) of the Olmsted County, MN population over age 40 underwent echo, record review and spirometry between 1997-2000 (Exam 1). A subset (n=1402) underwent repeat studies four years later (2001-2004; Exam 2). The current analysis includes the 723 subjects with paired PASP measurements. Changes ([[Unable to Display Character: ▵]]) in PASP, systemic arterial stiffness (pulse pressure; PP), LV filling pressure (E/e’) and lung function (% age/sex expected forced expiratory volume, %FEV1) were assessed. Results: At Exam 1, the median (interquartile range) age was 62 (69-70) years (62% female). Median time between exams was 48 (47-49) months. PASP increased from 26.1 (24.4-30.0) mmHg at Exam 1 to 28.0 (24.4-32.0) mmHg at Exam 2 (p<0.0001 by paired t test) for an average (SD) [[Unable to Display Character: ▵]] of 1.2 ± 5.5 mmHg. Adjusting for age and PASP at Exam 1, [[Unable to Display Character: ▵]]PASP was associated with [[Unable to Display Character: ▵]] age with an increase (parameter estimate (pe) ± standard error (se)) of 1.4±0.7 mmHg per year increase in age (p=0.046). [[Unable to Display Character: ▵]]PASP was not associated with sex and there was no age-sex interaction. Adjusting for age and PASP at Exam 1, [[Unable to Display Character: ▵]] age and Exam 1 values for PP, E/e or %FEV1 as appropriate, [[Unable to Display Character: ▵]]PASP was associated with [[Unable to Display Character: ▵]] PP (pe±se = 0.03±0.01 mmHg; p=0.01) [[Unable to Display Character: ▵]]E/e’ (pe±se = 0.21±0.06 mmHg, p=0.001) and [[Unable to Display Character: ▵]]%FEV1 (-0.09±0.02 mmHg, p<0.0001) suggesting that increases in PASP were related to increases in vascular stiffening, increases in LV filling pressures and declining lung function. Conclusions: In this longitudinal, population based study we find that PASP increases with aging and that increases in PASP over time are related to increases in systemic vascular stiffness and LV filling pressures and decreases in lung function.
At-Home Molecular Diagnostics: Just around the Corner or Years Away?
Karon, Brad S.

Mayo Clinic

The Journal of Applied Laboratory Medicine | January 3, 2024 | Volume: 9 | Issue: 1 | Pages: 168-171

10.1093/jalm/jfad070 | PMID 38167761 Get It

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
Couch, Steven M., Wester, Sara T. , Fowler, Brian , Liu, Catherine Y., Subramanian, Prem S. , Tang, Rosa A. , Nguyen, Quang T., Maamari, Robi N. , Karon, M , Douglas, Raymond S , Karon, Michael , Nguyen, Quang T, Ugradar, Shoaib , Hsu, Kate, Stan, Marius N.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 5, 2023 | Volume: 109 | Issue: 1 | Pages: 25-35

10.1210/clinem/dgad637 | PMID 37925673 Get It

AbstractContextEarly inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high-inflammation TED trials.ObjectiveWe present data from the first placebo-controlled trial with teprotumumab in chronic/low disease activity TED.MethodsThis randomized double-masked, placebo-controlled trial, conducted at 11 US centers, enrolled adult participants with TED duration of 2 to 10 years, Clinical Activity Score (CAS) ≤ 1 or no additional inflammation or progression in proptosis/diplopia for ≥1 year, proptosis ≥3 mm from before TED and/or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab, and no steroids within 3 weeks of baseline. Patients received (2:1) intravenous teprotumumab or placebo once every 3 weeks (total 8 infusions). The primary endpoint was proptosis (mm) improvement at Week 24. Adverse events (AEs) were assessed.ResultsA total of 62 (42 teprotumumab and 20 placebo) patients were randomized. At Week 24, least squares mean (SE) proptosis improvement was greater with teprotumumab (−2.41 [0.228]) than with placebo (−0.92 [0.323]), difference −1.48 (95% CI −2.28, −0.69; P = .0004). Proportions of patients with AEs were similar between groups. Hyperglycemia was reported in 6 (15%) vs 2 (10%) and hearing impairment in 9 (22%) vs 2 (10%) with teprotumumab and placebo, respectively. AEs led to discontinuation in 1 teprotumumab (left ear conductive hearing loss with congenital anomaly) and 1 placebo patient (infusion-related). There were no deaths.ConclusionTeprotumumab significantly improved proptosis vs placebo in longstanding/low inflammation TED, demonstrating efficacy regardless of disease duration/activity. The safety profile was comparable to that previously reported.
SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
Couch, Steven M., Wester, Sara T. , Fowler, Brian , Liu, Catherine , Tang, Rosa A. , Nguyen, Quang T., Karon, M , Douglas, Raymond S , Subramanian, Prem S. , Nguyen, Quang T, Hsu, Kate, Karon, Michael, Stan, Marius N.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.1930 Get It

Abstract Disclosure: R.S. Douglas: Consulting Fee; Self; Horizon Therapeutics plc, Immunovant, Viridian. S. Couch: None. S.T. Wester: Advisory Board Member; Self; Horizon Therapeutics plc. Consulting Fee; Self; Immunovant, Sling. B. Fowler: Consulting Fee; Self; Horizon Therapeutics plc. C. Liu: Other; Self; Walter Kluwer Health. P. Subramanian: Consulting Fee; Self; Gensight, Horizon Therapeutics plc, Viridian. R. Tang: Consulting Fee; Self; Viridian, Alexion, Valenza. Research Investigator; Self; Viridian, Horizon Therapeutics plc, Novartis, Immunovant, Vasaragen. Speaker; Self; Serono Speaker Journal Club. Q.T. Nguyen: None. K. Hsu: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizon Therapeutics plc. M. Karon: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizon Therapeutics plc. M.N. Stan: Consulting Fee; Self; Immunovant, Horizon Therapeutics plc, Sling, Genentech, ArgenX. Background: Thyroid eye disease (TED) is characterized by expansion of peri- and retro-orbital fat and muscle, often resulting in disfiguring proptosis (eye-bulging) and diplopia (double vision) which may persist chronically. Teprotumumab, an inhibitor of the insulin-like growth factor-1 receptor, demonstrated improvements in proptosis, diplopia, inflammation and quality of life in clinical trials in patients with TED history of short duration (6-13 months), and active disease (clinical activity score [CAS] ≥4). In a published study of 31 patients with CAS≤3 and TED duration &gt;2 years, teprotumumab reduced proptosis, diplopia and inflammation.1 We have undertaken the first randomized, placebo (PBO)-controlled trial to evaluate teprotumumab in patients with chronic/inactive/low CAS TED. The trial has completed randomization with results available in May 2023. Here we report characteristics of the randomized patients. Methods: The trial (NCT04583735) is being conducted in 11 centers in the United States. Key inclusion criteria were age≥18 years, TED duration ≥2 years but &lt;10 years and CAS≤1 in both eyes, ≥3mm proptosis from baseline and/normal for sex and race, or no progression in proptosis or diplopia or new inflammatory symptoms in the preceding year. Patients must have been euthyroid or mildly hypo/hyperthyroid, and not require surgical intervention through the trial. Patients could not have received teprotumumab previously, or steroids within 3 weeks before screening. Patients were randomized 2:1 to receive 8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) or PBO once every 3 weeks. The primary endpoint is improvement in proptosis (mm) as compared with PBO from baseline at Week 24. Other endpoints include percentage of proptosis responders (improvement of ≥2mm), diplopia responders (improvement of ≥1 grade in diplopia on the Bahn-Gorman scale, 0-3), and improvement in Graves’ Ophthalmopathy- Quality of Life (GO-QoL), all at Week 24. Adverse events (AE) and AE of special interest will be reported. Results: 62 patients were randomized. 80.6% are female, mean (SD) age was 48.7 (14.94) years. 54.8% are White, 24.2 %, Black or African American, and 12.9%, Asian. Mean (SD) TED duration was 5.2 (1.77) years. 87.1% are never/former smokers. At baseline, mean (SD) proptosis in the study eye was 24.4 (2.94) mm, and mean (SD) CAS was 0.4 (0.49). 27.4% had binocular diplopia with a mean diplopia score of 2. The mean overall GO-QoL score was 63.9 indicating similar disutility as observed in the acute trial population (previously published). Results from this 24-week trial will be presented. Conclusions: Despite a long duration of TED and low “activity”, patients enrolled in this trial have high levels of proptosis and impaired quality of life at baseline. Presentation: Saturday, June 17, 2023
OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
Couch, Steven M., Wester, Sara T. , Fowler, Brian , Liu, Catherine , Tang, Rosa A. , Nguyen, Quang T., Maamari, Robi N. , Karon, M , Douglas, Raymond S , Subramanian, Prem S. , Nguyen, Quang T, Hsu, Kate, Karon, Michael, Stan, Marius N.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.2055 Get It

Abstract Disclosure: R.S. Douglas: Consulting Fee; Self; Horizon, Immunovant, Viridian. Research Investigator; Self; Horizon. S. Couch: Research Investigator; Self; Horizon. S.T. Wester: Advisory Board Member; Self; Horizon. Consulting Fee; Self; Immunovant, Sling. Research Investigator; Self; Horizon. B.T. Fowler: Consulting Fee; Self; Horizon. Research Investigator; Self; Horizon. C. Liu: Research Investigator; Self; Horizon. Other; Self; Royalties from Wolters-Kluwer. P. Subramanian: Consulting Fee; Self; Horizon, Gensight, Viridian. Research Investigator; Self; Horizon. R. Tang: Consulting Fee; Self; Viridian, Alexion, Valenza. Research Investigator; Self; Horizon, Viridian, Novartis, Immunovant, Vasaragen. Speaker; Self; Serono Journal Club. Q.T. Nguyen: Research Investigator; Self; Horizon. R.N. Maamari: Research Investigator; Self; Horizon. K. Hsu: Employee; Self; Horizon. Stock Owner; Self; Horizon. M. Karon: Employee; Self; Horizon. Stock Owner; Self; Horizon. M. Stan: Consulting Fee; Self; Septerna Inc, Third Rock Ventures LLC, Genentech, MedicXi Ventures, ArgenX US Inc, Tourmaline Bio, Lassen Therapeutics, Ortho Clinical Diagnostics, Siemens Healthcare, Tolmar Inc, OSE, Immunotherapeutics, Roivant Sciences. Research Investigator; Self; Horizon, Immunovant, ValenzaBio, Sling Therapeutics. Background: Early inflammatory thyroid eye disease (TED) gives way to chronic disease which may lead to long-term disfiguring proptosis (eye-bulging). Teprotumumab, an IGF-1 receptor inhibitor, significantly improved signs and symptoms of newly diagnosed TED (6-13 months) with active disease (clinical activity score [CAS] ≥4) in prior studies. We present data from the first randomized, placebo (PBO)-controlled trial (NCT04583735) with teprotumumab in chronic/low CAS TED, where disease has not regressed. Methods: Pts met all following criteria: ≥18 yrs, TED 2-10 yrs, inactive disease or &gt;1 yr without progression in proptosis/diplopia/new symptoms, baseline (BL) CAS≤1, increased proptosis ≥3mm before TED or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab and no steroids within 3 wks of screen. Pts received teprotumumab or PBO once every 3 wks for 21 wks. Primary endpoint was improvement in proptosis(mm) from BL at Wk 24 vs PBO. Secondarily proptosis responders (≥2mm improvement), diplopia responders (≥1 grade improvement on Gorman scale 0-3) with resolved diplopia (grade 0) and improvement in Graves’ Ophthalmopathy-QoL (GO-QoL) visual function (VF) and appearance (AP) subscales were assessed. Treatment-emergent adverse events (TEAE) and AEs of special interest are reported. Study was solely sized/powered for proptosis. Results: 62 pts were randomized 2:1 (ITT, teprotumumab:42; PBO:20), 80.6% were female, mean(SD) age was 48.7(14.94) yrs. Mean(SD) TED duration was 5.2(1.8) yrs. 87.1% were never/former smokers. At BL, mean(SD) proptosis was 24.4(2.94) mm, mean CAS was 0.4, and 29% (teprotumumab, n=14, PBO, n=4) had diplopia with a mean score ∼2. 93%(39) of teprotumumab pts completed the study. At Wk 24, proptosis improvements from BL were significantly greater in the teprotumumab group [2.41 (0.228) mm] vs PBO [0.92(0.323) mm], P&lt;.001. Proptosis response was observed in 26/42 (62%) of teprotumumab pts vs 5/20 (25%) of PBO, P=.01. Diplopia improvement was observed in 6/14 (43%) teprotumumab pts with resolved diplopia in 4(29%) vs 2/4(50%) in PBO and 1(25%) resolved. Significantly greater improvement from BL was observed on GO-QoL-VF for teprotumumab (8.73) vs PBO (2.41), P=.03. Change from BL on AP was 10.03 vs 7.19, P= .65. TEAEs proportions were similar: 33/41(80.5%) of teprotumumab, and 16/20(80%) of PBO pts. Hyperglycemia was reported in 6(15%) vs 2(10%) and hearing impairment in 9(22%) vs 2(10%), respectively. There were two AE discontinuations: teprotumumab (left ear conductive hearing loss with congenital anomaly) and PBO (infusion related). Conclusions: For the first time in pts with longstanding TED and low CAS/inflammation, a medical therapy, teprotumumab, produced significant improvement in proptosis as compared with PBO supporting its use regardless of TED duration or activity. The safety profile was comparable to that previously reported. Presentation: Saturday, June 17, 2023
A-184 Racing Against the Clock: Process Improvement Project to Reduce Cardiac Troponin Turnaround Time Through Autoverification of Results
Tauferner, T M, Haga, Akira, Kelley, Barbara R, Wockenfus, Amy M., Karon, Brad S. , Katzman, Brooke M. , Haga, A J, Kelley, B R, Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.166 Get It

Abstract Background Turnaround time (TAT), defined as time of collection to time of result verification, is monitored monthly for cardiac Troponin (cTnT). Within our STAT laboratory, our TAT goal is 85% of cTnT results verified within 45 min. In October 2021, our lab began observing an increase in TAT. A quality improvement project was launched to identify a root cause and possible solutions. Methods cTnT TAT data from the Hospital Clinical Laboratory (STAT lab) at Mayo Clinic, Rochester, MN was extracted from our Laboratory Information System (LIS) using Tableau (Salesforce Inc., Seattle, WA). The data were categorized into three components: collection time, in lab processing and testing time, and time to result verification. Goal metrics for each component are: collection &lt;10 min, in lab processing and testing &lt;25 min, and result verification to LIS &lt;5 min. The average time for each component and percentage not meeting TAT goals were calculated in Microsoft Excel. TAT while performing manual verification of results (January 2022) and after autoverification was implemented (December 2022) were compared. Results Prior to implementation of cTnT autoverification, total orders for January 2022 were 1408 with 82.0% meeting TAT of 45 min. Of the 18.0% not meeting TAT, 207 (14.7%) orders exceeded goals for one or more components (percentages do not total 100%): collection delays 131 (63.0%), in lab processing and testing delay 175 (85.0%), and delay in result verification to LIS 80 (39.0%). For those orders not meeting the 45 min TAT goal, mean times were 17.6, 40.3, and 8 min for collection time, in lab processing and testing, and result verification to LIS, respectively. Post implementation of autoverification, total orders for December 2022 were 1444 with 88.6% meeting TAT of 45 min. Of the 11.4% not meeting TAT, 93 (6.4%) orders were outside goals for multiple components: collection delays 51 (55.0%), in lab processing and testing delay 67 (72.0%), and result verification to LIS 0 (0.0%) orders. For those orders not meeting the 45 min TAT goal, mean times 16.6, 39.7, and 0 min for collection time, in lab processing and testing, and result verification to LIS, respectively. Conclusion Achieving TAT goals agreed upon by the laboratory and clinical practice is critical to quality patient care. An investigation into our delayed TAT for cTnT highlighted several opportunities for intervention within the control of the lab. We chose to implement autoverification of results to easily and consistently eliminate the time required for manual result verification. TAT was improved by 6.6% (82.0% to 88.6%) through autoverification of results, allowing technologists to focus on other clinical work.
A-008 Comparison of Roche 5th Generation Troponin T Analytical Outlier Rates Between the e411 Analyzer Using a Biotin-sensitive Reagent and the e601 Analyzer Using Reformulated (Biotin-insensitive) Reagent
Kelley, Barbara R, Wockenfus, Amy M., Katzman, Brooke M. , Spears, Grant M. , Karon, Brad S. , Jaffe, Allan S. , Kelley, B R, Jaffe, Allan S. , Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.007 Get It

Abstract Background Analytical outliers (fliers) occur with most troponin methods and can adversely affect patient management. We compared the analytical outlier rates for the Roche 5th generation Troponin T STAT (cTnT) reformulated (biotin-insensitive) reagent using a Cobas e601 analyzer (Indianapolis, IN) to rates observed in a previous study using the biotin-sensitive reagent on a Cobas e411 analyzer. Methods Plasma separator tubes (PST) were collected from hospital patients with orders for clinical cTnT testing. PST samples were centrifuged for 3 min at 4000g and analyzed using the biotin-insensitive cTnT Gen 5 assay on a Roche Cobas e601 immunoassay system. If samples displayed measurable cTnT Gen 5 (≥6 ng/L), samples were stored at 2–8 °C within 2 h of initial measurement (N = 2555). Within 24 h of initial analysis, samples were warmed to room temperature, aliquoted, re-centrifuged at 4000g for 3 min, and cTNT was re-measured on the same analyzer. Outlier rates were compared to a previous study (N = 1997) using nearly identical study design but using biotin-sensitive Roche 5th Gen cTnT reagent on an e411 analyzer. We defined analytical outliers by three methods: Repeat value (after aliquoting and re-centrifugation) that differed from the initial value for all samples with measurable cTnT by a critical difference (CD): where CD = z × √2 × SDanalytical, with a z-value of 3.719 and using SD from best fit line of precision vs cTnT concentration. Precision experiments were performed using four plasma pools in 5 × 5 precision experiment on the e411 analyzer. Using the same CD but considering only initial cTnT values &lt;100 ng/L, those are most likely to be clinically significant or lead to misinterpretation. Using CD for initial values &lt;100 ng/L, and a fixed 10% difference between replicates for initial values ≥100 ng/L, accounting for our practice of reporting the cTnT “delta” in percent (rather than absolute) for values ≥100 ng/L. Comparisons of outlier rates between the biotin-sensitive and biotin-insensitive reagents were performed using Pearson’s chi-squared test. Results Using the CD the total number of outliers that were observed for the biotin-insensitive reagent on the e601 was 208/2555 (8.1%), compared to 68/1997 (3.4%) on the biotin-sensitive reagent measured on the e411 (P &lt; 0.0001). Outliers were observed in 138 (6.4%) of samples with initial values &lt; 100 ng/L using the biotin-insensitive reagent on the e601 compared to 45 (2.6%) of such samples on the e411 (P &lt; 0.0001). Using the Z score method to define outliers for initial values &lt;100 ng/L and a fixed 10% to define outliers for initial values ≥100 ng/L, the outlier rate was 151 (5.9%) for the biotin-insensitive reagent on the e601 compared to 53 (2.7%) on the e411 (P &lt; 0.0001). Conclusions Analytical outliers occurred more frequently using the reformulated (biotin-insensitive) reagent on the Roche Cobas e601 analyzer, compared to outlier rates observed for biotin-sensitive reagent on the Cobas e411.
A-373 Comparison of the CoaguChek ® and Coag-Sense ® PT2 Meter Point of Care INR Devices
Schumann, Thomas L. , Karon, Barry L., O’Connor, Clare , Jennifer, L, Blanco, J, Hartman, Lisa L.R., Uy, J. , Myhre, Nikki K., GAYLE, DAVID D., Hartung, K, David, H., Santrach, Paula J., O'Connor, C, Jennifer, L, Kramer, A, Hartung, K, David, H, McBane, Robert D.

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.329 Get It

Abstract Background Warfarin monitoring may be done at the point-of-care (POC) at home, in a clinic environment, or be performed using plasma specimens in a central laboratory. With a goal of standardizing International Normalization Ratio (INR) measurements and improving data integrity by enabling electronic transmission of results from any location, we evaluated two POC INR devices against an internal plasma INR reference method. Methods We conducted a multicenter study to test the accuracy of two commercially available point of care devices: Coag-Sense PT2 Meter (Coagusense, Inc., Fremont, CA) and CoaguChek XS Pro or XS Plus (Roche Diagnostics, Indianapolis, IN) compared with plasma INR values among warfarin treated patients. Bias and linear regression analysis were assessed for device-plasma INR comparisons. Warfarin dosing decisions were assessed for each device compared to an internal plasma INR reference method (Instrumentation Laboratories ACLTOP 500, 550, 750 analyzers (Werfen Diagnostics, Bedford MA) in one of three CLIA-certified laboratories. The thromboplastin used at our institution for INR measures is HemosIL RecombiPlasTin 2G (R2G) reagent (Werfen Diagnostics, Bedford MA) which has an International Sensitivity Index (ISI) of 1.0. Results Two hundred ninety-nine warfarin patients treated across three Mayo Clinic sites agreed to participate in the study. Common anticoagulant indications were atrial fibrillation (63.9%), venous thromboembolism (21.7%) and heart valve prosthesis (15.4%) with a 2.0–3.0 INR target range for 93.6% of patients. For the CoaguChek devices, 81.3% of values fell within 0.2 INR units of plasma INR referent and 95.3% within 0.4 units. The correlation between CoaguChek whole blood and plasma INR was excellent (R2 = 0.93). For the Coag-Sense device, 34.1% of values fell within 0.2 INR units and 60.2% within 0.4 INR units of plasma INR values, with a slightly weaker correlation between Coag-Sense whole blood and plasma INR (R2 = 0.83; P &lt; 0.0001). Mean (± standard deviation) deviation from plasma INR was 0.04 ± 0.2 for CoaguChek compared to 0.4 ± 0.3 for Coag-Sense (P &lt; 0.0001). The difference between POC devices was largely attributed to systematic negative bias between Coag-Sense and ACL TOP plasma INR values. Using the plasma INR as the reference method for dosing decision making, appropriate dosing recommendations would have occurred for 97.7% of CoaguChek and 81.6% of Coag-Sense results. Conclusion Compared to our institution's plasma reference method, INR values obtained from the CoaguChek devices (XS Pro and XS Plus) exhibited less systematic bias compared to the Coag-Sense values. This translates to greater percentage of concordant management decisions between POC and laboratory plasma INR methods when the CoaguChek device is used.
Cardiac troponin measurement at the point of care: educational recommendations on analytical and clinical aspects by the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (IFCC C-CB)
Aakre, Kristin M. , Saenger, Amy K., Body, Rick, Hammarsten, Ole, Jaffe, Allan S. , Kavsak, Peter A. , Omland, Torbjørn , Ordonez-Lianos, Jordi, Karon, Brad S. , Apple, Fred S. , Aakre, Kristin M , Karon, Brad, Collinson, Paul , Body, Rick, Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | January 13, 2023 | Volume: 61 | Issue: 6 | Pages: 989-998

10.1515/cclm-2022-1270 | PMID 36637984 Get It

Abstract The International Federation of Clinical Chemistry and Laboarator Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB) has provided evidence-based educational resources to aid and improve the understanding of important analytical and clinical aspects of cardiac biomarkers. The present IFCC C-CB educational report focuses on recommendations for appropriate use, analytical performance, and gaps in clinical studies related to the use of cardiac troponin (cTn) by point of care (POC) measurement, often referred to as a point of care testing (POCT). The use of high-sensitivity (hs)-cTn POC devices in accelerated diagnostic protocols used in emergency departments or outpatient clinics investigating acute coronary syndrome has the potential for improved efficacy, reduction of length of stay and reduced costs in the health care system. POCT workflow integration includes location of the instrument, assignment of collection and testing responsibility to (non-lab) staff, instrument maintenance, in-service and recurrent training, quality control, proficiency assessments, discrepant result trapping, and troubleshooting and inventory management.
Keep calm and invert on: Reducing blood recollection rates in the neonatal intensive care unit (NICU)
Ramos, Paola , Streeton, Abigail, Lunde, Julie, Legried, Michele, Karon, Bradley, Baumann, N

Mayo Clinic

American Journal of Clinical Pathology | November 9, 2022 | Volume: 158 | Issue: Supplement_1 | Pages: S7-S8

10.1093/ajcp/aqac126.012 Get It

Abstract Background Minimizing blood specimen recollection due to specimen integrity issues is a continuous quality improvement goal in the neonatal intensive care unit (NICU). Specimen integrity issues, such as clotting or hemolysis, are often the result of improper specimen collection processes and lead to blood loss requiring transfusion, additional painful procedures, and delays in patient care. Data collected from Mayo Clinic Hospital - Methodist Campus NICU at Mayo Clinic in Rochester, MN between January – July 2019 showed that clotted complete blood count (CBC) specimens accounted for one-third of rejected neonatal specimens followed by hemolyzed specimens for direct bilirubin (DBIL) testing. The aim of this project was to reduce the percent of CBC and DBIL tests canceled/specimens rejected due to specimen integrity issues in the NICU from 17% to 10% using the Plan-Do-Study-Act methodology. Methods A multidisciplinary quality improvement (QI) team was formed, inclusive of both NICU and laboratory representatives. Bedside direct observations (n=28) were performed by NICU nurses to help identify inconsistencies in the blood collection processes. A total of three Plan-Do-Study-Act (PDSA) cycles were conducted during the 2020-2021 time period. An assessment card was created and revised with each PDSA cycle. The card was completed by the nurse(s) present during the blood collection and initially identified the lab tests ordered, collection tubes, collection type (venipuncture, venous, capillary), number of tube inversions required, staff present during collection, any delays during collection, and whether the draw was deemed successful. Additionally, staff education videos for nursing and laboratory phlebotomy staff were created to demonstrate correct collection tube inversion technique. Results Direct observation identified inconsistent practices in tube inversion during specimen collection. The first PDSA cycle (n=207 collections, April 1 – July 13, 2021) introduced a verbal inversion count and utilization of the assessment card. The following cycle (n=336 collections, July 14 – October 10, 2021) implemented an educational video and modified the assessment card to include start and end time of the draw. The third cycle (n=243 collections, October 11 – November 30, 2021) used a simplified assessment card including patient label, tests ordered, tube type and inversions. The combined rejection rates for CBC and DBIL tests were 4.3%, 3.8% and 2.8% for the 1st, 2nd and 3rd PDSA cycles, respectively. Conclusions Our QI initiative reduced the specimen rejection rate for clotted CBC and hemolyzed DBIL specimens from 17% to 2.8% in the NICU. Interventions focused on improving tube inversion techniques and promoting collaborative relationships between phlebotomists and nursing staff. The use of educational videos and completion of assessment cards during collections were effective at reducing specimen rejection rates.